Inari Medical


Peripheral Interventional

Irvine, California | 200-500 employees

Opportunity Overview

Inari Medical has a unique story. In 2013, Inari Medical spun-out of the incubator Inceptus Medical after it developed two thrombectomy technology platforms for the treatment of peripheral vessels. These technologies were financially backed by prestigious MedTech venture capital firms, Gilde Healthcare, Versant Ventures, and U.S. Venture Partners.  Both technologies have FDA clearance, and in 2019 Inari Medical made history by being the most profitable MedTech startup in the first year of sales with $51 million in revenue. After going public in May, Inari Medical was named the best IPO debut of 2020.  Oh, and Inari Medical is named after a piece of sushi…inari sushi.

We have partnered with Ray Su, Head of Biostats, in hiring a Biostatistician for Inari Medical.  This newly created role will be responsible for statistical design and analysis of clinical research studies as well as for providing statistical expertise for publication efforts and regulatory submissions.


  • Provide input on publications and data analysis
  • Conduct exploratory analyses to inform design of new clinical trials
  • Conduct statistical analyses for data monitoring committees, if requested
  • Communicate statistical results to medical writing team to ensure accurate interpretation
  • Provide input on case report forms and clinical databases to ensure quality data collection
  • Provide statistical expertise and conduct ad hoc data analysis for publication/abstract submissions
  • Work closely with clinical teams in designing clinical studies and serve as statistical lead on multiple clinical studies
  • Collaborate with core stakeholders to provide statistical expertise in support of product development and regulatory submissions
  • Develop statistical analysis plans (SAP), conduct statistical analyses, and provide statistical input to clinical study reports (CSRs)
  • Program clinical research data for ease of analysis on ongoing basis, particularly for observational, hypothesis generating studies


  • MS or PhD in Statistics or Biostatistics
  • Knowledge of statistical methodologies
  • Understanding of data programming to facilitate statistical analyses

Who is Inari Medical?

Inari Medical, Inc. is a privately held venture backed medical device company dedicated to the development of innovative catheter-based technologies for the treatment of venous thromboembolism. Inari is focused on solutions that enable the safe removal of large clot volumes from big vessels without the use of thrombolytic drugs. Inari has developed two novel mechanical thrombectomy technology platforms. The FlowTriever System has FDA clearance for the treatment of pulmonary embolism and for thrombectomy in the peripheral vessels. The ClotTriever System has FDA clearance for thrombectomy in the peripheral vessels. Inari was founded in 2013 as a spin-out of Inceptus Medical, a medical device incubator. The company is backed by Gilde Healthcare (, Versant Ventures ( and U.S. Venture Partners (

Learn more at:

ClotTriever® Thrombectomy System

FlowTriever® System

Leadership Team

Bill Hoffman
Chief Executive Officer

View Bill’s LinkedIn Profile

Bill has focused on early stage companies with novel devices in new markets. Prior to Inari Medical, Bill served as CEO of Visualase, Inc., which developed and sold lasers for minimally invasive neurosurgery. The company was acquired by Medtronic for $105M in July, 2014, having raised less than $10m in equity funding. Prior to Visualase, Bill was Vice President of Sales at FoxHollow, Inc., helping to build a commercial team and revenue ramp that led to a successful IPO in 2004 and an acquisition by EV3 in 2007. Bill’s first early stage med tech experience was as head of sales at RITA Medical Systems, an interventional oncology company that enjoyed a successful IPO in 2000. He spent the early part of his career in various sales roles at Ethicon and Medtronic.

Tara Dunn
Vice President, Clinical Affairs and Market Development

View Tara’s LinkedIn Profile

Tara has extensive multi-functional medical device experience across a range of start-ups and larger organizations. Her most recent role was as the Venous Business Segment Leader at Volcano Corporation, acquired by Philips in 2015. Tara’s venous business experienced explosive triple digit growth in her time at the helm. Prior to Philips Volcano, she worked at Medtronic in Corporate Development where she participated in numerous transactions including the ~$816M acquisition of Kanghui Holdings in China and the divestiture of its Physio-Control business unit to Bain Capital for $487M. Tara also worked as a project leader at a healthcare strategy consulting firm called Health Advances and as Manager, Clinical and Regulatory Affairs at InfraReDx. She earned an A.B. in Biology from Harvard University, a M.S. in Regulatory Affairs and Health Policy from the Massachusetts College of Pharmacy and a M.B.A from Harvard Business School. Tara was a member of the National Championship winning ice hockey team and Ivy league championship team in softball while at Harvard. She also went on to compete in the National Women’s Hockey League (NWHL) for two seasons.

John Borrell
Vice President, Sales

View John’s LinkedIn Profile

John brings over 25 years of extensive commercial experience with early stage and mature medical device companies. His most recent roles were VP of Global Sales and Marketing at Trireme Medical and Area VP of Sales at Medtronic/Covidien Venous Vascular.  Prior to that he was VP of Sales and Marketing at Cardiovascular Systems Inc. (CSI), where he created/executed the commercial strategy driving revenue growth from $5M to $43M in year 1 of commercial launch.  Prior to CSI, John was the US Director of Sales at Fox Hollow Technologies where he played an integral role in the aggressive revenue ramp in their early commercial years.  Other successful start up’s that he was a part of prior to Fox Hollow: Novoste Corporation, Arterial Vascular Engineering and Heartport Inc. John earned his Bachelor of Science in Business Marketing from the University of Massachusetts at Lowell where he played Division 1 college hockey for four years.

Andrew "Drew" Hykes
Chief Commercial Officer

View Andrew’s LinkedIn Profile

Drew is a proven medical device operating executive with broad functional, geographic and sector experience.  From 2012-2016 Drew served as the VP of Commercial Operations at Sequent Medical where he led the commercialization strategy for the WEB Aneurysm Embolization system from early prototype to broad adoption in the European market.  Sequent was acquired by Terumo Corporation in July 2016 for $380 million.  Prior to Sequent, Drew spent 11 years at Medtronic.  His roles at Medtronic included the VP of Marketing for the AF Solutions business, VP of Clinical and Regulatory for the AF Solutions business and Director of Investor Relations.  Drew also spent three years on an expatriate assignment in Europe leading the launch of Medtronic’s first drug eluting coronary stent.  Prior to Medtronic, he spent four years at ABN AMRO bank in Chicago focused on healthcare transactions.  He earned a B.B.A. in Finance from the University of Wisconsin and an MBA from Harvard Business School.

Eric Khairy
Vice President, Marketing

View Eric’s LinkedIn Profile

Eric holds over 15 years of medical device experience in marketing, sales, strategy, and product development. Following the acquisition of Volcano by Philips in 2016, Eric progressed from leading global peripheral venous marketing to driving strategy of the peripheral vascular segment at Philips Image-Guided Therapy Devices. Joining Corindus Vascular Robotics in the company’s pre-commercial phase in 2012, Eric launched the first FDA cleared robotic-assisted system for percutaneous coronary interventions. Prior to Corindus, Eric led Intuitive Surgical’s launch and distribution of the da Vinci Surgical System in the Canadian market at Minogue Medical. Eric earned a B.Eng. in computer engineering from McGill University, an M.A.Sc. in biomedical engineering from the University of Montreal, and an MBA from the Sloan School of Management at MIT.